February 16, 2018 07:31 AM EST

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

John Carroll

Editor & Founder

A little less than two years after tiny, San Diego-based Apricus Biosciences $APRI decided to cut its staff and concentrate the survivors on an erectile …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Tiny Apri­cus’ sur­vival strat­e­gy nixed for now by FDA re­jec­tion of erec­tile dys­func­tion ther­a­py, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks